Oruka Therapeutics Inc

Oruka Therapeutics (OTC: ORUK) sees analyst upgrades and a $73 buy target as clinical trials advance its heart‑failure gene‑therapy pipeline, despite 2025 losses.

Oruka Therapeutics Inc. has seen a significant stock surge after announcing positive Phase 1 clinical data for its treatment for chronic plaque psoriasis and securing a $180 million capital infusion, drawing investor attention and analyst optimism.

Oruka Therapeutics has promoted Laura Sandler to Chief Operating Officer, bringing over 20 years of biopharmaceutical experience to the role as the company advances its pipeline of novel biologics for chronic skin diseases.